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Objective: Pro-opiomelanocortin (POMC)-derived peptides act on neurons expressing the Melanocortin 4 receptor (MC4R) to reduce body
weight. Setmelanotide is a highly potent MC4R agonist that leads to weight loss in diet-induced obese animals and in obese individuals with
complete POMC deﬁciency. While POMC deﬁciency is very rare, 1e5% of severely obese individuals harbor heterozygous mutations in MC4R. We
sought to assess the efﬁcacy of Setmelanotide in human MC4R deﬁciency.
Methods: We studied the effects of Setmelanotide on mutant MC4Rs in cells and the weight loss response to Setmelanotide administration in
rodent studies and a human clinical trial. We annotated the functional status of 369 published MC4R variants.
Results: In cells, we showed that Setmelanotide is signiﬁcantly more potent at MC4R than the endogenous ligand alpha-melanocyte stimulating
hormone and can disproportionally rescue signaling by a subset of severely impaired MC4R mutants. Wild-type rodents appear more sensitive to
Setmelanotide when compared to MC4R heterozygous deﬁcient mice, while MC4R knockout mice fail to respond. In a 28-day Phase 1b clinical
trial, Setmelanotide led to weight loss in obese MC4R variant carriers. Patients with POMC defects upstream of MC4R show signiﬁcantly more
weight loss with Setmelanotide than MC4R deﬁcient patients or obese controls.
Conclusions: Setmelanotide led to weight loss in obese people with MC4R deﬁciency; however, further studies are justiﬁed to establish whether
Setmelanotide can elicit clinically meaningful weight loss in a subset of the MC4R deﬁcient obese population.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Neural circuits in the hypothalamus play a critical role in the regulation
of energy homeostasis [1,2]. Peripheral nutrient-derived signals such
as leptin stimulate the expression of Pro-opiomelanocortin (POMC)-
derived melanocortin peptides, which reduce food intake and body
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www.molecularmetabolism.commelanocortin-4 receptor (MC4R) [3,4]. MC4R knockout mice are
severely obese while loss of one MC4R allele results in an intermediate
obesity phenotype demonstrating that weight regulation is sensitive to
quantitative variation in MC4R expression [5]. Obesity-associated
MC4R mutations conﬁrm a role for MC4R-mediated signaling in hu-
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Brief Communicationbe modulated by accessory proteins such as melanocortin receptor
accessory protein 2 (MRAP2) [11e13].
In view of these effects, MC4R, which is a seven-transmembrane
domain G-protein coupled receptor (GPCR), has been considered as
a potential drug target for the treatment of obesity [14e16]. However,
ﬁrst generation MC4R agonists resulted not only in suppression of food
intake and induction of weight loss, but also in a signiﬁcant increase in
blood pressure (BP) and heart rate (HR) in rodents, primates, and
humans [16e19]. For example, treatment of obese volunteers with the
agonist LY2112688 at the maximum dose of 1.0 mg/day led to sig-
niﬁcant increases of systolic (mean 9.3  SD 1.9 mmHg) and diastolic
(mean 6.6  SD 1.1 mmHg) blood pressure after only 24 h of treat-
ment compared with placebo [18]. These adverse effects halted the
development of the ﬁrst generation of MC4R agonists.
Setmelanotide (formerly known as RM-493 or BIM-22493) is a syn-
thetic cyclic peptide that binds to human MC4R with high afﬁnity,
activates MC4R at nanomolar concentrations (50% effective concen-
tration [EC50] ¼ 0.27 nM), and has been shown to reduce food intake
and body weight and restore insulin sensitivity in diet-induced obese
(DIO) mice, rats, dogs, and monkeys [20,21]. Comparable weight loss
effects have been observed in genetic animal models of obesity treated
with Setmelanotide, although not in MC4R knockout mice [22], indi-
cating that the effects of Setmelanotide are indeed due to its action on
MC4R. Importantly, in Rhesus monkeys with diet-induced obesity,
Setmelanotide infused at 0.50 mg/kg/day for 8 weeks led to signiﬁcant
decreases in food intake (w40%) and body weight (w13%) without
acute or long-term increases in BP or HR measured by continuous
telemetry [20]. Additionally, drug-related changes in heart rate and
blood pressure were not observed in a series of Setmelanotide phase
1b/2a or experimental studies in obese individuals [21].
In a recent proof-of-principle study, two rare POMC deﬁcient individuals
treated with Setmelanotide experienced signiﬁcant weight loss (51.0 kg
of bodyweight loss after 42weeks in patient 1 and 20.5 kg of bodyweight
after 12 weeks in a second patient) without any adverse effects on
cardiovascular parameters [23]. These results established that while
obesity due to complete POMC deﬁciency is very rare, it is potentially very
responsive to treatment with Setmelanotide. Heterozygous loss of
function (LOF) mutations in MC4R are found more frequently with
prevalence estimates ranging from 1 to 5% in children or adults with
severe obesity [9,10,24]. This group of individuals are relatively refractory
to weight loss through diet and exercise [25] and other treatment options
remain limited. Roux-en-Y bypass surgery can be effective, but is not
without risks and not suitable for many people [26]. We hypothesized that
Setmelanotide might lead to weight loss in MC4R deﬁciency by rescuing
signaling by mutant MC4Rs and/or by increasing signaling through the
wild type MC4R allele. We therefore performed a series of studies, which
included a detailed interpretation of the functional status of 369 MC4R
variants as well as preclinical and clinical studies in a small subset of
variants to address the impact of MC4R mutations or Setmelanotide
treatment on energy homeostasis in MC4R deﬁciency.
2. MATERIALS AND METHODS
2.1. Cohorts
UK: Ethical approval for studies was given by the Cambridge Research
Ethics Committee; all participants gave written informed consent. The
Genetics of Obesity Study (GOOS) is a cohort of 7000 individuals with
severe early-onset obesity; age of obesity onset is less than 10 years.
Severe obesity is deﬁned as a body mass index (BMI, weight in ki-
lograms divided by the square of the height in meters) standard de-
viation score  3 (SDS, calculated according to the United Kingdom2 MOLECULAR METABOLISM- (2017) 1e9  2017 The Authors. Published by Elsereference population). MC4R sequencing was performed as described
previously.
France: Subjects were patients followed-up in the Department of
Nutrition of Trousseau hospital (for children), Hôtel-Dieu and Pitié-
Salpêtrière hospital for adults (Paris, France). They were part of a
genetic study of severe obesity (Clinical Research program PHRC 0702)
with similar inclusion criteria of the UK cohort. Clinical investigations
were approved by the Ethics Committee of Hôtel-Dieu hospital. All
subjects gave their written informed consent. MC4R sequencing was
performed at UF Genetic of Obesity and Dyslipidemia of Hôtel-Dieu and
Pitié-Salpêtrière hospitals (J.L.B., D.P., J.M.L.).
2.2. Systematic review of literature on MC4R variants
To assess the functional consequences of all published MC4R muta-
tions, we searched all studies on functional cell-based assays of MC4R
variants. We systematically reviewed articles containing the terms
“MC4R” or “mc4-r” indexed on MEDLINE from inception to August
31st, 2016 in addition to bibliographies of manually selected articles,
mutations published by human genetic databases (1000 Genomes
release 16, Exome Variant Server ESP6500SI-V2) and unpublished
data from our labs. Because functional consequences of MC4R mu-
tations are assessed and reported in a wide variety of ways, we
devised an a priori semi-quantitative scale of the overall residual
function. Each non-synonymous mutation could lead to a complete
LOF, a partial LOF, or no LOF (wild type like). In addition, contradictory
and unclear published data resulted in ambiguous status for many
variants. Functional assay data were collected for each published
MC4R variant: cell line, cell surface expression, tested ligands (a-MSH,
b-MSH, g1-MSH and artiﬁcial agonists such as NDP-a-MSH, mela-
notan [MT-II]), Emax (efﬁcacy, the maximum level of cAMP production in
response to increased doses of a given ligand), EC50 (potency, the
concentration of a ligand eliciting half of the maximum response in
cAMP production), and in a competitive binding assay Bmax (the
maximal binding capacity to a ligand) and IC50 (afﬁnity, the concen-
tration of a ligand binding half the receptors). All functional data were
normalized to wild type levels, to enable comparison between articles
(Figures S1eS2). The assay data were independently abstracted by
three authors (T.-H.C., B.D., A.G.) and compared to reach a consensus
on the residual function of each variant. Discrepancies were discussed
among co-authors to reach a consensus on the residual function of
each MC4R variant. Ambiguous variants were re-evaluated in a head-
to-head comparison of activity in cell-based assays (see section
Functional characterization of additional MC4R variants).
2.3. Comparison of response to alpha-MSH and Setmelanotide in
cell-based assays
Setmelanotide (formerly known as RM-493 or BIM-22493) is a synthetic
8 amino-acid, cyclic peptide MC4R agonist with a molecular formula of
C49H68N18O9S2 (anhydrous free base) and molecular weight of
1117.3 Da. Setmelanotide binds with high afﬁnity to the human MC4R
(inhibitory constant [Ki]¼ 2.1 nmol/l) and is efﬁcient in activating MC4R
(EC50¼ 0.27 nmol/l) [20]. Activation of other melanocortin receptors by
Setmelanotide requires concentrations that are more than 20-fold or
higher than for MC4R: the EC50 was 5.8 nmol/l with MC1R, 5.3 nmol/l
with MC3R, and >1 mmol/l for MC5R. Setmelanotide displayed no
activity for the MC2R, also known as the adrenocorticotropic hormone
(ACTH) receptor. This compound was initially selected for clinical
development based on the extended circulating half-life in non-human
primates (2.8e3.5 h). For the data shown in Figure 2, MC4R wild type
and mutant cDNAs were cloned into DiscoverX expression vectors (RPN-
MC4R (variant)-PK 7293 bp). The sequences of the inserts were fullyvier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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veriﬁed and conﬁrmed to be 100% identical to the expected nucleotide
sequences. The receptors were introduced into U2OS cells expressing
arrestin-AE. Cells were placed under antibiotic selection to ensure
stable integration of the fusion gene construct. Expression level of each
of the mutants and wild type proteins was tested. The stably transfected
cell pools were plated for agonist measurements in the DiscoverX cAMP
and PathHunter arrestin assays.
2.4. Functional characterization of MC4R variants in cell-based
assays
In order to characterize newly identiﬁed MC4R variants or to clarify
classiﬁcation of variants for which the systematic review of published
data returned ambiguous results, we performed in vitro assays in
transiently transfected HEK293 cells. We assessed relative cell surface
expression of the mutant receptors in cell-based ELISA and we
employed the cAMP response element-binding protein (CREB) trans-
reporting system (Stratagene) to examine the impact of these vari-
ants on the receptor signaling activity via cAMP dependent pathway.
MC4R cDNA constructs barring an N-terminal FLAG tag in
pCDNA3.1(þ) vector (Invitrogen) were used throughout the study. Site-
directed mutagenesis was performed using QuikChange kit (Agilent)
according to the manufacturer’s protocols. All constructs were veriﬁed
with Sanger sequencing. HEK293 cells were maintained in high
glucose Dulbecco’s modiﬁed eagle medium (DMEM, Gibco, 31966)
supplemented with 10% fetal bovine serum (Gibco, 10270, South
America origin), 1% GlutaMAX (100X) (Gibco, 35050), 100 units/mL
penicillin, and 100 mg/mL streptomycin (SigmaeAldrich, P0781). Cells
were incubated at 37 Celsius degrees in humidiﬁed air containing 5%
CO2 and transfections were performed using Lipofectamine 2000
(Gibco, 11668) in serum-free Opti-MEM I medium (Gibco, 31985)
according to the manufacturer’s protocols. Brieﬂy, 40,000 cells/well
were seeded in a poly-D-lysine coated 96-well plate and transfected
the next day with either 30 or 5 ng of MC4R constructs, for cell surface
expression ELISA and CREB reporter assay, respectively.
2.4.1. Cell surface expression
Cells transfected with FLAG-tagged MC4R constructs were tested for
cell surface localization of the receptor with ELISA. Two days after
transfection, cells were ﬁxed with 3.7% paraformaldehyde for 15 min
at room temperature and washed three times with PBS. Subsequently,
non-speciﬁc binding sites were blocked with 3% non-fat dry milk in
50 mM Tris-PBS pH 7.4 (blocking buffer) for 1 h at room temperature.
Next, cells were incubated with a mouse monoclonal anti-FLAG (M2)
antibody (SigmaeAldrich, F1804) (dilution 1:1000 in blocking buffer)
overnight at 4 Celsius degrees followed by triple washing with PBS and
incubation with goat anti-mouse IgG(H þ L)-HRP conjugate (Bio-Rad
Laboratories, 172-1011) (1:1250 in 1.5% non-fat dry milk in 50 mM
Tris-PBS pH 7.4) for 2 h at room temperature. Finally, plates were
washed three times with PBS and a high performance chromogenic
substrate e 3,30,5,50 tetramethylbenzidine (TMB COREþ, Bio-Rad
Laboratories, BUF062) was used to detect HRP activity. The reaction
was terminated with 0.2M H2SO4 and absorbance by the color reaction
product at 450 nm was determined using Inﬁnite M1000 PRO
microplate reader (Tecan).
2.4.2. CREB-luciferase reporter assay
In order to detect MC4R signaling activity, HEK293 cells were tran-
siently co-transfected with a respective MC4R construct, a trans-
activator plasmid pFA2-CREB and a reporter plasmid, pFR-Luc at 5,
6 and 25 ng/well, respectively. On the following day, cells were
stimulated with increasing concentration of a-MSH for 5 h. The CREB-MOLECULAR METABOLISM- (2017) 1e9  2017 The Authors. Published by Elsevier GmbH. This is an ope
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(Perkin Elmer, 6066759). Brieﬂy, cells were washed with Dulbecco’s
modiﬁed PBS (DPBS) supplemented with 0.9 mM CaCl2 and 0.5 mM
MgCl2 (Gibco, 14040). DPBS and ready-to-use luciferase substrate
were dispensed in equal volumes, and luminescence was quantiﬁed
after 20 min using TopCount Microplate Counter (Packard). All results
were analyzed using GraphPad Prism 6 (GraphPad Software). Relative
cell surface expression is presented as means  SEM of three to four
independent experiments, each normalized to basal signal for mock
transfected cells and MC4R WT expression level in a given assay.
CREB-luciferase reporter assays were carried out in triplicates and
were independently replicated at least three times. Results of each
experiment were normalized to basal signal for mock transfected cells
and maximal efﬁcacy of a-MSH for MC4R WT in a given assay. Pre-
sented doseeresponse curves were plotted from the merged
normalized data analyzed with 4-parameter non-linear regression
equation.
2.5. Setmelanotide administration in animals
For the duration of the Setmelanotide studies, rodents were single-
housed in an IACUC approved facility at Vanderbilt University. Wild-
type (Mc4r þ/þ), heterozygous (Mc4r þ/) and MC4R null (Mc4r /)
mice were placed on a high fat diet (Research Diets, Inc. #D12451,
45% kcal fat, 35% kcal carb, 20% kcal protein) at 11 weeks of age,
which continued for the duration of the experiment. At 13 weeks of
age, the animals were placed in a Promethion Sable monitoring system
for 3 days to acclimatize and to obtain baseline measurements. After
the acclimatization period, animals were weighed and surgically
implanted with primed Alzet minipumps (Alzet #1002, 0.25 mL/h
infusion rate) delivering saline alone, or 1200 nmol/kg/day of Set-
melanotide dissolved in saline. The pumps were placed subcutane-
ously on each animal’s upper back. Animals were monitored for food
and water intake, then removed from the Promethion cages, and
weighed once more 9 days after the implant. Statistical analyses were
performed using Graphpad Prism 5.
2.6. Setmelanotide clinical trial
The clinical trial protocol was reviewed and approved by Schulman
Associates Institutional Review Board, 4445 Lake Forest Drive, Suite
300 Cincinnati, OH 45242, USA. All clinical trial participants provided
informed consent prior to enrolling in the study (ClinicalTrials.gov
Identiﬁer: NCT02431442).
Weight: All measurements were performed in triplicate throughout the
study. The same scale was used throughout the study, including the
screening visit, and was calibrated daily. Weight was measured when
individuals were fasted at approximately the same time each day.
Individuals were in scrubs, with no shoes and an empty bladder. In-
dividuals were blinded to their weight throughout the study.
Waist circumference: All measurements were performed in triplicate.
Measurements occurred during screening, at baseline, once weekly
during treatment, and at the follow-up visits.
Vital signs: Blood pressure (BP) and heart rate (HR) were obtained in
the supine position following at least 5 min of rest each time they were
measured. Pre-dose measurements were taken in triplicate, approxi-
mately 2 min apart; the means of these triplicate measurements
served as the baseline values. All other BP and HR time-points were
single measurements. When possible, BP was taken in the same arm
as it was taken at pre-dose baseline. For the ﬁrst day, vitals were taken
every hour for the ﬁrst 12 h, then every 2 h. On Day 2, vitals were taken
every 12 h, followed by once daily thereafter. On days 8, 14, 22, and
28, vitals were taken every 12 h.n access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 3
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provided by CoreLab Partners, Rockville, MD 20850, USA. The ABPM
monitor was worn continuously for a minimum of 24 h at 3 timepoints
throughout the study: baseline, approximately mid-way through dosing
duration, and at the end of dosing. The ABPM device was programmed
to take readings every 20 min during the 24-hour monitoring period.
Quantitative skin color measurements: Quantitative skin measure-
ments were performed with a spectrophotometric device, the
Mexameter-18, Courage þ Khazaka Electronic, GmbH, Cologne,
Germany. The amount of melanin in the skin was measured at the 3
following locations representing various degrees of sun exposure for a
total of 3 times each and the values were averaged: On the cheek of
the subject, directly under the pupil on the zygomatic arch, on the
forehead of the subject, midline about an inch above eyebrows, and on
the upper, outer, right buttock (‘hip’). Measurements were taken prior
to dosing, weekly during dosing, and at follow-up visits.
3. RESULTS
3.1. A single system for functional annotation of MC4R mutations
We generated a single functional classiﬁcation system for variants in
MC4R as not all variants impact MC4R signaling in cell based assays
and this has caused some confusion in the ﬁeld. Moreover, while some
classiﬁcation schemes have been proposed [14,27e29], these remain
difﬁcult to apply uniformly given the discordant and/or incomplete
functional data available in different publications. We systematically
reviewed and collated data on all published MC4R variants and
included unpublished data on 75 variants from our labs (Figure 1A,
Figures S1e2). In total, we identiﬁed missense (n ¼ 318, 69.7%),
nonsense (n ¼ 24; 5.3%), and frameshift mutations (n ¼ 21; 4.6%)
and deletions (n ¼ 6; 1.3%). There were inconsistencies between the
reported functional consequences of a subset of variants. To enable
reliable classiﬁcation of these variants, we performed functional as-
says on 22 MC4R variants with unknown, incomplete or ambiguous
functional status for which we had clinical data; 5 resulted in a
complete LOF, 14 in a partial LOF and 3 were wild type (WT)-like
(Figure 1BeD, Table S1). We have made the functional classiﬁcation
dataset with MC4R functional assay data, available as a searchable
resource (Table S2, www.mc4r.org.uk).
Using this functional classiﬁcation, we examined phenotypic data
from 224 children and 264 adults carrying MC4R mutations. We
found that MC4R variant homozygotes were signiﬁcantly more obese
than heterozygotes (p < 0.001); there was no signiﬁcant difference
in BMI between those carrying heterozygous complete vs partial LOF
variants (Figure 1E). We did not identify signiﬁcant genotypee
phenotype correlations for most phenotypes after adjusting for age,
gender, and BMI (data not shown). Of interest, we found that children
heterozygous for complete LOF variants consumed slightly more at
an ad libitum test meal (mean 121.1 kJ/kg lean mass  SEM 12.3)
than those with partial LOF mutations (mean 82.2 kJ/kg of lean
mass  SEM 10.4), although this was not statistically signiﬁcant
(p ¼ 0.07, Figure 1F). This effect was more pronounced when
analyzing the data for children under 10 years of age (mean
154.7 kJ/kg lean mass  SEM 13.2 in complete LOF, 96.6  15.2
in partial LOF; p ¼ 0.02, Figure 1G). One possible explanation is that
young children may be less inﬂuenced by the presence of observers
in the research setting. There was a similar trend for homozygous
carriers of MC4R variants but with limited statistical power due to the
small number of individuals. These ﬁndings support the notion that
variation in melanocortin tone is a key modulator of human energy
intake.4 MOLECULAR METABOLISM- (2017) 1e9  2017 The Authors. Published by Else3.2. Setmelanotide rescues signaling by MC4R mutants in vitro
As MC4R is known to be a Gas-coupled GPCR [30], we studied the
ability of increasing agonist concentrations to induce cyclic AMP
(cAMP) in transiently transfected cells expressing WT or mutant
MC4Rs, measuring the maximal response (Emax) and the agonist po-
tency (EC50). We have previously shown that Setmelanotide exhibits
nanomolar potency in a cAMP accumulation assay (EC50 ¼ 0.27 nM)
[21]. In our cell based reporter system Setmelanotide is about 10e20
fold more potent than the endogenous ligand a-MSH at WT MC4R.
Here, we tested the ability of Setmelanotide to rescue a randomly
selected group of published MC4R variants (Figure 2). We found that
Setmelanotide was signiﬁcantly more potent than a-MSH for all tested
variants. However, there was considerable variation in the magnitude
of the rescue response (deﬁned as EC50 a-MSH/EC50 Setmelanotide)
with Setmelanotide being up to 500-fold more potent than aMSH at
some mutant MC4Rs (e.g. E61K and G55D) (Figure 2).
3.3. Setmelanotide administration in MC4R null and MC4R
heterozygote null mice
We studied the effect of Setmelanotide administration in mice lacking
Mc4r. Wild-type (Mc4r þ/þ), heterozygous null (Mc4r þ/), and a small
number of homozygous null (Mc4r /) mice were placed on a high fat
diet (45% kcal fat) and then implanted with subcutaneous osmotic
pumps containing either 1200 nmol/kg/day Setmelanotide or vehicle
(saline); body weights were monitored for 9 days. All saline treated
groups gained weight in response to the high fat diet. Mc4r þ/þ mice
treated with Setmelanotide exhibited weight loss, while Mc4r / mice
treated under the same conditions, gained a comparable amount of
weight to their vehicle-treated controls. Setmelanotide-mediated
weight loss seemed to be mediated by a reduction in food intake,
rather than changes in activity or energy expenditure (Figure S3),
although the magnitude of the effect was small in these studies.
Interestingly, Mc4rþ/- mice exhibited an intermediate response to
Setmelanotide treatment as evidenced: i) by a reduction in absolute
weight gain over the period (Figure 3A); ii) when comparing weight
gain to baseline in treated mice (Figure 3B); and iii) the Setmelanotide-
mediated improvement in body weight over saline (Figure 3C) (the
latter corrects for the weight gain seen in vehicle-treated mice on the
high fat diet). Overall, it is apparent that Mc4r þ/þ and þ/ mice lose
weight with Setmelanotide, with wild-type mice being the most sen-
sitive to treatment, while Mc4r / mice do not respond (as also
shown previously [22]).
3.4. Clinical response to Setmelanotide: a phase 1b trial in MC4R
deﬁciency
We examined the effects of Setmelanotide on weight loss in ran-
domized, double blind placebo controlled Phase 1b trials. A total of 49
healthy obese (BMI 26.2e40.3 kg/m2) individuals between the ages of
19e53 years (41 males and 8 females) were enrolled in 5 cohorts and
randomized to treatment with either Setmelanotide or placebo for 14 or
28 days via continuous subcutaneous infusion. Generally, each cohort
enrolled nine individuals, six active and three placebo. MC4R was
sequenced in all participants; one subject was identiﬁed as hetero-
zygous for a predicted partial loss of function variant (G252S), whereas
all other individuals had a normal coding sequence and were thus
referred to as Obese Controls. A sixth cohort of healthy obese (BMI
31.5e51.7 kg/m2) people between the ages of 22e57 years (2 males
and 6 females) known to be heterozygous for complete or partial loss
of function mutations in MC4R were enrolled in the trial and received
0.01 mg/kg/24 h for 28 days. The previously identiﬁed subject (G252S)
from Cohort 4 was enrolled in this MC4R heterozygote cohort (Table 1).vier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1: Genetic and molecular classiﬁcation of MC4R mutations. (A) MC4R is a seven transmembrane domain GPCR with 3 intracellular loops (ICL), 3 extracellular loops
(ECL), and a C-terminal helix 8 (H8); schematic adapted from GPCRDB Tools [41]. Colors denote amino acids that have been altered by mutations. Functional consequences of
these mutations were classiﬁed following a systematic review of the literature (Figure S1). Where multiple variants affecting the same amino acid have been reported, the most
severe loss of function (LOF) mutation is shown. (BeD) Functional characterization of 22 new MC4R mutations. a-MSH stimulated cAMP generation was assessed in transiently
transfected cells using a CREB-luciferase reporter assay (Table S1). Data are mean  SEM of 4 experiments. (EeG). Genotype-phenotype correlations in 249 children with
complete or partial loss of function MC4R mutations (cLOF/pLOF respectively). Data are represented as mean  SEM. (E) Body mass index (BMI) standard deviation scores (SDS) of
children who were homozygous (Hom) for cLOF (n ¼ 16) or pLOF mutations (n ¼ 17) were compared to those who were heterozygous (Het) for cLOF (n ¼ 131) or pLOF (n ¼ 85)
MC4R mutations. Homozygotes had a signiﬁcantly higher BMI SDS than those with heterozygous MC4R mutations (p < 0.001 with and without adjustment for age, sex and
ethnicity), while there was no statistically signiﬁcant difference between those with cLOF or pLOF mutations within the same gene dosage group (both p ¼ 1.00). (F) Ad libitum food
intake adjusted for lean mass measured by dual energy X-ray absorptiometry in 57 children (age < 18 years) (Hom cLOF (n ¼ 6); Hom pLOF (n ¼ 3); Het cLOF (n ¼ 29); Het pLOF
(n ¼ 19)). (G) Ad libitum food intake adjusted for lean mass in 35 children age < 10 years (Hom cLOF (n ¼ 5); Hom pLOF (n ¼ 2); Het cLOF (n ¼ 17); Het pLOF (n ¼ 11)) (data on
obese children have been reported previously [10].
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Figure 2: Effects of Setmelanotide in cells expressing different MC4R variants. The cAMP response to a-melanocyte stimulating hormone (a-MSH) and Setmelanotide was studied
for wildtype (WT) and 17 mutant forms of MC4R; mean EC50 (concentration required to elicit 50% of the maximal response) of experiments performed in duplicate with 11 point
dose titrations. Some variants (R18C, V50M, I102T, G231S, R305W) have been studied previously and values were taken from the relevant reference [42]. The ability of Set-
melanotide to rescue signaling by MC4R mutants was calculated (EC50 of a-MSH/EC50 of Setmelanotide) and varied considerably between mutants. The ratio could not be
precisely determined for some variants (G55D, E61K, C271Y) because of the high concentrations of a-MSH needed.
Brief CommunicationAlthough the total number of individuals in each cohort of this Phase 1
trial was small, signiﬁcant weight loss was observed in all Obese
Control cohorts receiving 0.01 mg/kg/24 h of Setmelanotide
compared to placebo (Table 1). In the MC4R mutation carriers, placebo
subtracted group mean differences in weight loss (dose 0.01 mg/kg/Figure 3: Effect of Setmelanotide administration in mice lacking Mc4r. Mc4r þ/þ,
(saline), using an implanted subcutaneous minipump. (A) Body weight before (day 0) and a
Setmelanotide treated groups. Each symbol represents a single test animal’s change in bo
with Bonferroni post-test. (C) Setmelanotide mediated 9-day weight improvement over sali
change in saline treated groups from the average body weight change in Setmelanotide trea
to saline would be represented by a weight difference of zero. Values displayed are Mean
*P < 0.05; **P < 0.01.
6 MOLECULAR METABOLISM- (2017) 1e9  2017 The Authors. Published by Else24 h) ofw0.6 kg/week were observed (Table S3). Although this result
did not reach statistical signiﬁcance (p ¼ 0.09) when compared to
placebo, weight loss from baseline was signiﬁcantly reduced
(p < 0.0001). Weight loss was accompanied by reductions in waist
circumference (Table 1).þ/, and / mice were infused with 1200 nmol/kg/day of Setmelanotide, or vehicle
fter (day 9) among all treatment groups. (B) Cumulative 9-day weight change among all
dy weight. Statistical signiﬁcance between groups is calculated using one-way ANOVA
ne treated groups. These values are calculated by subtracting the average body weight
ted groups (DSetmelanotide  DSaline). A treatment that causes no change compared
þ/ SD and statistical signiﬁcance is calculated using a T-test versus saline controls.
vier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table 1 e Changes in weight and waist circumference with Setmelanotide in heterozygous MC4R deﬁciency and obese controls.
Treatment arm Heterozygous MC4R deﬁciency Obese controls
Baseline,
mean  SD
Day 29,
mean  SD
Change from
baseline, mean
(95% CI)
P-value Baseline,
mean  SD
Day 29,
mean  SD
Change from
baseline, mean
(95% CI)
P-value
Weight, kg
Setmelanotide 130.46  22.96 126.98  22.96 3.48 (4.99, 1.96) <0.0001 97.86  17.18 94.79  16.50 3.07 (4.11, 2.04) <0.0001
Placebo 101.75  21.71 100.90  23.29 0.85 (3.48, 1.78) 0.52 98.26  7.99 99.16  7.30 0.90 (0.44, 2.24) 0.18
Comparison of Setmelanotide vs. placebo 2.63 (5.66, 0.41) 0.09 e 3.97 (5.67, 2.28) <0.0001
Waist circumference, cm
Setmelanotide 132.8  18.1 127.0  17.4 5.83 (9.70, 1.96) 0.005 107.2  8.9 105.4  8.5 1.80 (2.72, 0.88) 0.0004
Placebo 112.3  13.1 111.5  13.4 0.75 (7.45, 5.95) 0.82 112.3  12.4 113.0  13.0 0.67 (0.52, 1.85) 0.26
Comparison of Setmelanotide vs. placebo 5.08 (12.82, 2.66) 0.19 e 2.47 (3.96, 0.97) 0.002
Randomized, double blind placebo controlled trial of Setmelanotide subcutaneous infusion 0.01 mg/kg/day vs placebo for 28 days in heterozygous carriers of melanocortin 4 receptor
mutations (MC4R, n ¼ 6 on Setmelanotide and n ¼ 2 on placebo list of variants in Table S3) and obese controls (right section, 5 subjects on setmelanotide and 3 on placebo). Mean
weight and waist circumference values (3 readings) were averaged and compared with ANOVA of change from baseline as the dependent variables and treatment, day and the
interaction as factors.In view of the previous adverse effect proﬁle of MC4R agonists, HR and
BP were frequently monitored throughout the 14- to 28-day treatment
periods for each dose, and for 24 h after completion of treatment. 24-
hour ambulatory BP monitoring (ABPM) was performed on a baseline
day, halfway through treatment and on the last dosing day of each
cohort. There was no increase in HR or BP at any dose in either obese
control or MC4R mutation carriers treated with Setmelanotide, as seen
in other clinical studies with Setmelanotide. The adverse events (AEs)
observed in this study were generally well-tolerated, mild, and inter-
mittent. As is common in Phase 1 studies, AEs were extensively
collected, and most of these AEs (except tanning) were also reported in
the placebo group. AEs reported after repeated administration of
Setmelanotide regardless of dose included: skin discoloration (tanning)
(56.4%), headache (33.3%), skin lesions (17.9%), nausea (15.4%),
penile erections (12.8%), infusion site pain (12.8%), and diarrhea
(10.3%). In general, there were no differences in the frequency of
these effects between the Obese Control and MC4R deﬁcient groups.
The most frequently reported adverse effect of Setmelanotide was skin
tanning, which increased gradually at doses 0.01 mg/kg/24 h
reaching a plateau byw2 weeks in most people. This effect was likely
explained by activation of the closely related MC1R (Setmelanotide
potency on MC1R ¼ 5.8 nM). As well as clinical assessments of skin
pigmentation, skin color was assessed quantitatively using a Mexa-
meter. At baseline, individual inter-subject variability was high
(reﬂecting ethnicities of participants); however, the intra-subject vari-
ability was low. For example, in one placebo group studied over 2
weeks, the baseline mean score for six individuals was 297.56 units
and the 2-week post-dose (placebo) response was 290.22 units. In
contrast, in the Setmelanotide treated Obese Controls, the baseline
score in six individuals was 331.11 units, and the 2-week post-dose
(active) value was 521.33 units, a result that was statistically signiﬁ-
cant (p < 0.0001) even in this small group of individuals. All patients
were followed to resolution following active dosing (w2e6 weeks).
4. DISCUSSION
Our ﬁndings demonstrate that the melanocortin 4 receptor agonist,
Setmelanotide can lead to weight loss in obese people with MC4R
deﬁciency (on average 0.6 kg/week). Importantly, Setmelanotide
induced weight loss over 4 weeks without eliciting an increase in HR or
BP, in contrast to other MC4R agonists tested to date. Additional
studies are needed to determine whether the data presented here are
effective predictors of weight loss in larger studies enrolling cohorts ofMOLECULAR METABOLISM- (2017) 1e9  2017 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.compatients carrying complete and partial MC4R LOF variants. Such
studies may also provide information about the mechanisms by which
weight loss occurs. A potential mechanism that could contribute to the
efﬁcacy of Setmelanotide in such patients is a chaperone effect,
whereby agonists (or antagonists) can rescue mutant forms of the
MC4R by restoring their expression at the cell surface. A number of
prior studies have also shown that a subset ofMC4R variants appear to
be rescued in this manner when studied in cells with distinct MC4R
agonists [31e33].
In a head-to head comparison of Setmelanotide and a-MSH, we found
that some variants were rescued more efﬁciently than others, espe-
cially those with a high mutant/wild type EC50 ratio. At present the
structure of the MC4R has not been determined, although homology
modeling on MC1R has been used to suggest possible structural ex-
planations for the molecular mechanisms by which mutations result in
a LOF [31]. Interestingly, we ﬁnd an overrepresentation of non-
synonymous variants in transmembrane domain (TM)-I, intracellular
loop-1 (ICL-1), TM-II, the intracellular part of TM-VII, and helix 8, do-
mains which form a so-called hydrogen bond network which has been
demonstrated to play an important role in receptor activation and
signaling speciﬁcity [34,35]. There are surprisingly few LOF variants in
the N-terminal domain and in extracellular segments of the inward
looking parts of transmembrane domains which constitute the large
binding pocket (TM-III, TM-IV, TM-V, TM-VI, TM-VII). Further studies
will be needed to more fully characterize the mutants reported here
and the mechanisms by which a subset are rescued by Setmelanotide.
Given the large number of possible MC4R variants, we were fortunate
to ﬁnd one patient enrolled who carried the heterozygous C271Y MC4R
variant, which was earlier, independently classiﬁed as being dis-
proportionally efﬁciently rescued by Setmelanotide in cells. Indeed, this
patient was one among three complete LOF MC4R variant carriers
treated with Setmelanotide who showed a profound weight loss
response (0.9 kg/week). This could be a basis for future patient
stratiﬁcation whereby certain patients might beneﬁt more readily from
Setmelanotide treatment than others.
Possible reasons for the cardiovascular proﬁle of Setmelanotide,
compared to previous MC4R agonists, might be that some lead
compounds tested to date differentially penetrate the CNS [36] and, at
these sites, may couple through different G-protein signaling path-
ways. Recently, Weinstein and colleagues showed that disruption of
melanocortin receptor Gas and Gaq11 signaling in the paraventricular
nucleus of the hypothalamus, led to divergent phenotypes in rodents
[37], and several studies have shown that MC4R signaling is moren access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 7
Brief Communicationcomplex than previously thought including evidence of biased signaling
[38] and evidence for diverse ligands exhibiting distinct temporal
cellular signaling selectivity [39].
We have shown that individuals with MC4R deﬁciency as well as those
expressing the wild type MC4R lose weight following Setmelanotide
treatment. Current preclinical and clinical MC4R pathway deﬁciencies
treated with Setmelanotide indeed predict an order of Setmelanotide
treatment sensitivity where MC4R pathway upstream mutations
(POMC) are more sensitive to Setmelanotide treatment than wild type
genotypes [40], which appear, in turn, more responsive to Setmela-
notide than most MC4R LOF variants. We anticipate that stratiﬁcation
of patients harboring mutations in the leptin-melanocortin pathway,
which include the pro-opiomelanocortin, proprotein convertase sub-
tilisin/kexin type 1, leptin receptor and defects in MC4R, will help
targeting Setmelanotide to the genetic subgroups that can optimally
respond to treatment with this promising drug candidate.
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